Covid-19 has been a rough go for many drugmakers, but few more so than Spectrum Pharmaceuticals, which has seen inspection delays and unwanted CRLs haunt its chance at a first approval. Feeling the…
As the CEO of RNA editing startup Korro Bio, Ram Aiyar often gets the same question. ‘I get always asked, you know, if you can fix DNA, why bother with RNA?’ he told Endpoints News. ‘And it’s like…
Throughout the past two years, North Carolina Gov. Roy Cooper has been building a biotech manufacturing empire in his state, expanding beyond the Research Triangle and offering tax breaks to…
Business in China is booming, with more than a thousand biotech and biopharma companies — including some big multinational players — flocking to Zhangjiang Pharma Valley to take advantage of a growing…
GE Healthcare has been in a collaborative mood as of late, striking a spate of partnerships in the last six months with a goal of improving various facets of clinical care.
Annexon found out the hard way that investors do read the fine print. Despite the small biotech reporting ‘promising’ interim results from a midphase Huntington’s disease trial, the company saw its…
Ticket sales for Korro Bio’s second operatic financing round landed at $116 million as the biotech builds up an investor base to bankroll its OPERA platform for RNA editing.
GlaxoSmithKline has successfully overtaken the shingles vaccine market once owned by Merck, but enter king Pfizer. The Big Pharma juggernaut has signed a third deal with COVID-19 vaccine partner…
Thermo Fisher Scientific started off the new year with a new member to its family, closing a $1.85 billion acquisition to build out its recombinant protein catalog.
Merck KGaA is taking a fourth option in its deal with bispecific immunotherapy biotech F-Star Therapeutics, which has attracted the eyes of a who’s who of Big Pharma. The latest Merck option will…
